Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long
Antibody Products Will Be An Important Option Until Vaccines Reduce Infections
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
You may also be interested in...
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
Regeneron's antibody cocktail prevented deaths and mechanical ventilation in hospitalized patients on low-flow oxygen. Also, Pfizer and BioNTech will supply an additional 100m doses of the companies' COVID-19 vaccine to the US government for $1.95bn, while Merck & Co signed a contract for its COVID-19 treatment MK-7110.